Gore Range Capital

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Eirion Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of advanced prescription products for aesthetic dermatology. The company's product pipeline includes treatments aimed at addressing various conditions such as wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion is committed to meeting significant unmet clinical needs within the field, with plans to explore additional indications in the future. Through its innovative approach, Eirion Therapeutics aims to provide effective solutions for both physicians and patients dealing with aesthetic concerns.